Axon Plunged To a 2-Year Low. Here's Why It Could Be a Golden Buying Opportunity

AXON (AXON) dropped 18% to a two-year low after missing third-quarter revenue estimates, and the culprit is a single delayed order: a $30 million Federal Dedrone deployment that slipped out of the quarter.

The miss came with two additional negatives. Axon cut its free cash flow guidance and reported weak Taser sales, giving the sell-off more than one leg. Still, management argued that underlying demand remains strong, framing the revenue shortfall as a timing problem rather than a demand problem.

Analysts are leaning that way too. Per the source, they view the stock as potentially undervalued given its historical growth trajectory and solid business fundamentals, which is the basis for the "golden buying opportunity" thesis.

Interpretation: the market appears to be pricing the guidance cut and Taser weakness as more than a one-off. An 18% drop on a deployment worth $30 million suggests investors read the delay alongside the cash flow reduction as a signal about near-term earnings quality. If the Dedrone revenue simply shifts into a later quarter, the miss could prove transitory; if Taser softness persists, the discount may be warranted.